Eledon Pharmaceuticals has converted a Phase 2 kidney program into a funded Phase 3 design, and the quarter reduced the gap between that design and the first patient enrolled. The End-of-Phase 2 meeting with the FDA fixed the trial framework, and the company plans to initiate the global kidney trial in late 2026. That regulatory alignment is the load-bearing event of the quarter, and the framing the company used, establishing the regulatory framework, is the honest read of what actually happened.
The tension is capital. Cash and short-term investments ended the quarter at $88.8 million, down from a year-ago balance of $133.3 million. First-half operating cash use ran at $45.3 million, which is the burn rate the runway math is built on. The company expects that balance to fund operations into the second quarter of next year. That is roughly two quarters of runway before the Phase 3 enrollment costs scale up, and it is the number that defines the funding urgency.
The print itself is modest for a pre-revenue biotech. Net loss widened to $31.6 million for the quarter, roughly triple the year-ago loss. The widening is inflated by a non-cash warrant liability charge, so the operating story is flatter than the headline. The forward question is whether the company can close the funding gap before first Phase 3 patient in without terms that leave existing holders materially diluted.